Related Experiment Videos
Lithium augmentation of venlafaxine: an open-label trial
E Hoencamp1, J Haffmans, W A Dijken
1Parnassia, Psycho-Medical Centre, The Hague, The Netherlands.
Journal of Clinical Psychopharmacology
|September 23, 2000
Summary
This study found that adding lithium to venlafaxine treatment is a safe and effective strategy for patients with depression who do not respond to venlafaxine alone. Lithium augmentation improved depression scores in treatment-resistant individuals.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Medicine
Background:
- Depression is a prevalent mood disorder often requiring multifaceted treatment approaches.
- Treatment resistance in depression necessitates exploring augmentation strategies for improved patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and tolerability of venlafaxine.
- To assess the effectiveness of lithium augmentation in outpatients with depression unresponsive to venlafaxine.
Main Methods:
- An open-label study involving outpatients (18-70 years) with depression (HAM-D score ≥16).
- Venlafaxine was administered with dose escalation over 7 weeks.
- Non-responders (<50% HAM-D decrease) received lithium carbonate augmentation (600 mg/day), with dose adjusted for target plasma levels (0.6-1.0 mmol/mL).
- Efficacy assessed using HAM-D, Montgomery-Asberg Depression Rating Scale, and Clinical Global Impressions Scale.
Main Results:
- After 7 weeks, 35% of patients achieved ≥50% decrease in HAM-D scores with venlafaxine alone.
- Lithium augmentation was initiated in 23 patients.
- Lithium addition was well-tolerated, leading to further HAM-D score reduction, with 8 responders and 2 achieving remission.
Conclusions:
- Venlafaxine monotherapy shows moderate efficacy in this patient cohort.
- Lithium augmentation is a well-tolerated and effective strategy for treatment-resistant depression when added to venlafaxine.
- This combination approach offers a viable option for improving outcomes in non-responsive depression cases.